标题
Laquinimod treatment in the R6/2 mouse model
作者
关键词
-
出版物
Scientific Reports
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-07-04
DOI
10.1038/s41598-017-04990-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons
- (2016) Dagmar E. Ehrnhoefer et al. EXPERIMENTAL NEUROLOGY
- Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
- (2016) Lucianne Dobson et al. JOURNAL OF NEUROCHEMISTRY
- The immunomodulatory effect of laquinimod in CNS autoimmunity is mediated by the aryl hydrocarbon receptor
- (2016) Johannes Berg et al. JOURNAL OF NEUROIMMUNOLOGY
- Mutant Huntingtin Impairs BDNF Release from Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDP
- (2016) Y. Hong et al. JOURNAL OF NEUROSCIENCE
- Impaired TrkB Signaling Underlies Reduced BDNF-Mediated Trophic Support of Striatal Neurons in the R6/2 Mouse Model of Huntington’s Disease
- (2016) Khanh Q. Nguyen et al. Frontiers in Cellular Neuroscience
- Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease
- (2016) Marta Garcia-Miralles et al. Scientific Reports
- Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTRup-regulation and astrocyte-mediated inflammation
- (2015) Andrés Miguez et al. HUMAN MOLECULAR GENETICS
- The role of laquinimod in modulation of the immune response in relapsing–remitting multiple sclerosis: Lessons from gene expression signatures
- (2015) R. Zilkha-Falb et al. JOURNAL OF NEUROIMMUNOLOGY
- HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFκB pathway dysregulation
- (2014) Ulrike Träger et al. BRAIN
- Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis
- (2014) Kalliopi Pitarokoili et al. JOURNAL OF NEUROIMMUNOLOGY
- Targets for future clinical trials in Huntington's disease: What's in the pipeline?
- (2014) Edward J. Wild et al. MOVEMENT DISORDERS
- Impaired TrkB Receptor Signaling Underlies Corticostriatal Dysfunction in Huntington’s Disease
- (2014) Joshua L. Plotkin et al. NEURON
- Huntington’s disease: pathogenesis to animal models
- (2014) Puneet Kumar et al. Pharmacological Reports
- Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
- (2014) Manoj Kumar Mishra et al. Annals of Clinical and Translational Neurology
- A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease
- (2013) Han-Yun Hsiao et al. HUMAN MOLECULAR GENETICS
- Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease
- (2013) S. H. Stuwe et al. NEUROLOGY
- Huntington's disease: underlying molecular mechanisms and emerging concepts
- (2013) John Labbadia et al. TRENDS IN BIOCHEMICAL SCIENCES
- Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
- (2012) Wolfgang Brück et al. ACTA NEUROPATHOLOGICA
- Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases
- (2012) Antero Salminen et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis
- (2012) Rina Aharoni et al. JOURNAL OF NEUROIMMUNOLOGY
- Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
- (2012) Giancarlo Comi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor
- (2011) Jan Thöne et al. AMERICAN JOURNAL OF PATHOLOGY
- Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis
- (2011) Jan Thöne et al. Expert Opinion on Drug Metabolism & Toxicology
- Insight into the mechanism of laquinimod action
- (2011) W. Brück et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease
- (2011) Elahe Taherzadeh-Fard et al. Molecular Neurodegeneration
- The role of IκB kinase complex in the neurobiology of Huntington's disease
- (2011) Ali Khoshnan et al. NEUROBIOLOGY OF DISEASE
- Hdac6 Knock-Out Increases Tubulin Acetylation but Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease
- (2011) Anna Bobrowska et al. PLoS One
- TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons
- (2011) M. Baydyuk et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mitochondria and Huntington's Disease Pathogenesis
- (2010) Susan E. Browne Annals of the New York Academy of Sciences
- Laquinimod suppress antigen presentation in relapsing–remitting multiple sclerosis: In-vitro high-throughput gene expression study
- (2010) M. Gurevich et al. JOURNAL OF NEUROIMMUNOLOGY
- Mitochondria in Huntington's disease
- (2009) Maria Damiano et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Brain-derived neurotrophic factor in neurodegenerative diseases
- (2009) Chiara Zuccato et al. Nature Reviews Neurology
- Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients
- (2008) H. Seo et al. HUMAN MOLECULAR GENETICS
- Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
- (2008) G Comi et al. LANCET
- Mutant huntingtin and mitochondrial dysfunction
- (2008) Ella Bossy-Wetzel et al. TRENDS IN NEUROSCIENCES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started